Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
OMER vs ENTA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
OMER Captures Overall Composite Edge (54.1 HOLD vs 46.2 HOLD), While ENTA Leads 3–2 on Growth & Valuation Pillars
OMER Overall Winner
6-Pillar Tally: OMER 2 – 3 ENTA (1 Tie)
Matrix Metrics: OMER 7 – 3 ENTA
As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (54.1/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 7–3 (led by Growth & Scale, Options & Positioning), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. OMER trades at $17.18 (75.8x Forward P/E, -189.5% operating margin) versus ENTA at $10.79 (44.0x Forward P/E, -90.0% operating margin).
- Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.81β · 54% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: OMER trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.9); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OMER vs ENTA
OMER
Head-to-Head Winner
Omeros Corporation
$17.18
-1.8% 1D
Market Cap
$1.3B
TTM Revenue
$27M
Forward P/E
75.8x
Beta / 30D Vol
1.81β · 54% Vol
Unified Composite Score
54.1
HOLD
Tech 44.0
Fund 55.0
Flow 74.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
ENTA
Enanta Pharmaceuticals, Inc
$10.79
-1.82% 1D
Market Cap
$326.2M
TTM Revenue
$65M
Forward P/E
44.0x
Beta / 30D Vol
0.89β · 58% Vol
Unified Composite Score
46.2
HOLD
Tech 53.0
Fund 54.0
Flow 67.0
Mom 50.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (OMER 2 – 3 ENTA)
1. Valuation Multiples
ENTA
Forward P/E
75.8x
44.0x
Trailing P/E
14.9x
44.0x
PEG Ratio
0.81x
N/M
EV / Revenue
51.9x
5.3x
2. Growth & Scale
OMER
Revenue Growth (YoY)
+14.9%
-21.6%
Earnings Growth (YoY)
+0.0%
-66.2%
TTM Revenue (USD)
$27M
$65M
Market Cap
$1.3B
$326.2M
3. Profitability & Quality
ENTA
Gross Margin
38.3%
100.0%
Operating Margin
-189.5%
-90.0%
Net Profit Margin
324.9%
-96.9%
Return on Equity (ROE)
-576.3%
-70.1%
4. Balance Sheet & Cash Flow
ENTA
Cash Generation (TTM)
-$48M
-$37M
Cash Flow Margin
N/A
-56.6%
Net Cash / Leverage
$96M Net Debt
$22M Net Debt (0.55x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
OMER
Options Structure Phase
CONSOLIDATION
BREAKDOWN
Current IV / %ile
147.9% (99th %ile)
78.7% (11th %ile)
Put/Call OI Skew
0.09x (Call-Skewed)
0.31x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OMER (7) vs ENTA (3)| Institutional Metric | OMER | ENTA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.3B | $326.2M | OMER | |
| Trailing P/E Ratio | 14.9x | 44.0x | OMER | |
| Forward P/E Ratio | 75.8x | 44.0x | ENTA | |
| Revenue Growth (YoY) | +14.9% | -21.6% | OMER | |
| Operating Margin (TTM) | -189.5% | -90.0% | ENTA | |
| Net Profit Margin | 324.9% | -96.9% | OMER | |
| Return on Equity (ROE) | -576.3% | -70.1% | ENTA | |
| 52-Week Range Position | 73% ($6–$21) | 10% ($10–$17) | OMER | |
| Beta / 30D Volatility | 1.81β · 54% Vol | 0.89β · 58% Vol | OMER | |
| Unified Institutional Score | 54.1 / 100 (HOLD) | 46.2 / 100 (HOLD) | OMER | |
| Trailing 12M Revenue (USD) | $27M | $65M | Scale | |
| Gross Profit Margin (TTM) | 38.3% | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | 0.81x PEG · 51.9x EV/Rev | N/M PEG · 5.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$48M ($96M Net Debt) | -$37M ($22M Net Debt (0.55x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
OMER +8.81 pp
3M Horizon
OMER +18.78 pp
6M Horizon
OMER +66.57 pp
1Y Horizon
OMER +181.43 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OMER Revenue | ENTA Revenue | OMER Op. Margin | ENTA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $30M | $210M | -375.7% | 42.7% | ENTA |
| FY2019 | $110M | $210M | -130.6% | 17.9% | ENTA |
| FY2020 | $70M | $120M | -212.6% | -34.0% | ENTA |
| FY2021 | N/A | $100M | N/A | -112.9% | ENTA |
| FY2022 | N/A | $90M | N/A | -143.7% | ENTA |
| FY2023 | N/A | $80M | N/A | -173.2% | ENTA |
| FY2024 | N/A | $70M | N/A | -179.9% | ENTA |
| FY2025 | N/A | $70M | N/A | -130.7% | ENTA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OMER
CONSOLIDATION
Current IV
147.9%
IV Percentile
99th %ile
Put/Call OI Skew
0.09x (Call-Skewed)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact OMER Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ENTA
BREAKDOWN
Current IV
78.7%
IV Percentile
11th %ile
Put/Call OI Skew
0.31x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OMER Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ENTA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ OMER vs ENTA Key Questions & Quantitative Answers
As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (54.1/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 7–3 (led by Growth & Scale, Options & Positioning), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. OMER trades at $17.18 (75.8x Forward P/E, -189.5% operating margin) versus ENTA at $10.79 (44.0x Forward P/E, -90.0% operating margin). Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.81β · 54% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OMER trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.9); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OMER leads the Growth & Scale pillar: OMER posts +14.9% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (38.3% gross margin, -189.5% operating margin), compared with ENTA at -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OMER cumulative revenue shifted +133.3% while ENTA shifted -66.7%. In operating R&D and SG&A reinvestment, OMER deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTA.
ENTA screens cheaper on headline valuation multiples. OMER trades at 75.8x Forward P/E, 14.9x Trailing P/E, 0.81x PEG, and 51.9x EV/Revenue (unreported FCF margin), whereas ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OMER (-576.3% ROE) versus ENTA (-70.1% ROE) capital efficiency.
In options market volatility and institutional positioning, OMER carries 147.9% implied volatility (99th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.81β · 54% Vol realized risk). By comparison, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ENTA vs OMER · Reverse Pair
OMER vs OCUL
· Sector Peer
OMER vs PTCT
· Sector Peer
OMER vs TGTX
· Sector Peer
ENTA vs XNCR
· Sector Peer
ENTA vs PTCT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem